LA Pediatric Auditory Brainstem Implant Clinical Trial Awarded Unprecedented NIH Grant
House Research Institute (HRI) and Children’s Hospital Los Angeles announced today final approval of grant funding by the National Institutes of Health (NIH) National Institute on Deafness and Communications Disorders (NIDCD) for a major five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.
Children's Hospital Los Angeles Chief of Medical Staff Mark Krieger, MD, head of the hospital's Neurosurgery division and Billy and Audrey Wilder Endowed Chair in Neurosurgery, will be part of the surgical team in a new clinical trial on the auditory brainstem implant for children. (Photo: Business Wire) “We are grateful to the NIDCD for funding our study at House/Children’s Hospital, which represents the first time the NIDCD has funded a pediatric ABI clinical trial,” said Eric P. Wilkinson, MD, co-principal investigator, House Research Institute, lead physician on the study, and associate, House Clinic.
Marc S. Schwartz, M.D., ABI neurosurgeon and investigator, and neurosurgeon at House Neurosurgical Associates at the House Clinic, agreed. “The clinical trial grant provides us with vital funding to begin phase one of our surgical trial of the pediatric ABI in the U.S.” Mark Krieger, M.D., pediatric neurosurgeon and chief of medical staff, Children’s Hospital Los Angeles, and Billy and Audrey Wilder Endowed Chair in Neurosurgery, completes the surgical team. Study surgeries will be performed at the Children’s Hospital. “We are extremely excited to bring this revolutionary technology to Children’s Hospital. We are especially looking forward to offering this innovative procedure to provide sound to deaf children in the United States,” Krieger said.
Children considered for the clinical trial must have congenital bilateral deafness resulting from a malformed or non-existent cochlea or hearing nerve. Such patients cannot receive hearing benefits from a hearing aid or cochlear implant. Children with cochlear implants that have not provided benefit are also suitable candidates for the study. Ten U.S. children will have their surgical and audiological care provided by the trial grant.
The ABI was developed at HRI in the late 1970s and is the world’s first successful prosthetic hearing device to stimulate neurons directly at the human brainstem, bypassing the inner ear and hearing nerve entirely. More than 1,000 adults worldwide have received the ABI, led by physicians of the House Clinic.
The goal of the study is to establish the safety of both the ABI and the delicate brain surgery procedures required for its successful implantation for American children. To date, children who have been implanted with ABIs outside the U.S. have demonstrated potential to understand speech, and five U.S. children who were implanted in Europe in recent years receive regular follow-up by the pediatric audiology staff at HRI’s CARE (Children’s Auditory Research and Evaluation) Center in Los Angeles.
“For the children we have been evaluating in the CARE Center, communication outcomes have been shown to vary. However, we are impressed by the rate at which some of these children are learning to recognize speech without visual cues,” said Laurie Eisenberg, Ph.D., co-director, House Research Institute’s CARE Center, and audiologist and co-principal investigator on the grant.
An example of the promising communication results of the pediatric ABI is the story of Nathan Goss: Implanted in Italy in 2008 at the age of 3, Nathan was one of the first U.S. children to receive an ABI. According to his parents and HRI’s CARE Center clinical team, Nathan, who is now 7 years old, is communicating well enough to be successful in 2nd grade in at mainstream elementary school.